TwinStrand DuplexSeq measuring MRD in AML


At TwinStrand we put science first in everything we do. We routinely present at academic conferences to share our own discoveries as well as those made with our many collaborators across the scientific spectrum.

An Updated Duplex Sequencing Mutagenesis Assay Accurately and Reproducibly Detects Mutation Frequencies Below One-In-Ten-Million

An AML targeted Duplex Sequencing assay can detect Measurable Residual Disease (MRD) at a sensitivity better than 0.01% Variant Allele Frequency

Novel DNA Standards for Assessing Technical Sensitivity and Reproducibility Duplex Sequencing Mutagenesis Assays

Duplex Sequencing for mutagenesis testing in wild type rodents and a common human cell line

Ultra-Sensitive Duplex Sequencing for Quantifying Multi-Individual Cell Therapy Sub-Population Fractions

Duplex Sequencing reveals ubiquitous clonal hematopoiesis and complex donor-recipient clonal dynamics following hematopoietic stem cell transplant

Longitudinal monitoring of pediatric acute myeloid leukemia using duplex sequencing of patient-specific panels reveals ultra-low frequency MRD that marks persistent carcinogenesis and complex clonal evolution

Ultra-Sensitive Duplex Sequencing for Tracking of Allogeneic Cell Therapies

Detection of Ultra-rare Mutations in vivo Establish biomarkers of Endogenous and Environmental Exposure

Duplex Sequencing Detects Rare Subclonal Variants that Mark Early Carcinogenesis and Preneoplastic Clonal Evolution

Duplex Sequencing for MRD Detection in Acute Myeloid Leukemia

Super CHIP: Duplex Sequencing Reveals Clonal Dynamics in Blood that are Magnitudes more Complex than Previously Recognized

Non-invasive Detection of Aristolochic Acid Exposure Using Ultra-Sensitive Duplex Sequencing


Redefining “Gold Standard” Ultra-Sensitive Characterization of Commercial DNA Standards with Duplex Sequencing